Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.40 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391439 | 1.00 | SMO (0.40) | SMOSGPL1CXCR3PTGDR2HSD11B1 | |
| SCHEMBL13590956 | 0.92 | SMO (0.39) | SMOSGPL1CXCR3PTGDR2HSD11B1 | |
| SCHEMBL4241889 | 0.92 | SMO (0.39) | SMOSGPL1CXCR3PTGDR2HSD11B1 | |
| SCHEMBL4248845 | 0.92 | SMO (0.39) | SMOSGPL1CXCR3PTGDR2LIPE | |
| SCHEMBL13590966 | 0.92 | SMO (0.39) | SMOSGPL1CXCR3PTGDR2LIPE | |
| SCHEMBL4246579 | 0.90 | LMNA (0.40) | SMOSGPL1PTGDR2CHRM2CHRM1 | |
| SCHEMBL13590967 | 0.90 | LMNA (0.40) | SMOSGPL1PTGDR2CHRM2CHRM1 | |
| SCHEMBL4074520 | 0.87 | SMN1; SMN2 (0.46) | HSD11B1 | |
| SCHEMBL4392834 | 0.87 | HIF1A (0.40) | SMOSGPL1CXCR3PTGDR2 | |
| SCHEMBL4250515 | 0.86 | SMO (0.46) | SMOSGPL1CXCR3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | claimed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | claimed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | SMO 1890/4885SGPL1 656/4885CXCR3 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.